|Table of Contents|

The predictive value of baseline NLR and PLR for early efficacy of immunotherapy in locally advanced head and neck squamous cell carcinoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 19
Page:
3683-3688
Research Field:
Publishing date:

Info

Title:
The predictive value of baseline NLR and PLR for early efficacy of immunotherapy in locally advanced head and neck squamous cell carcinoma
Author(s):
ZHANG Wenying1; HUAN Haihua1; HU Xiaohua1; WANG Jiongyi1; LIU Feng2
1.Department of Oncology,the Ninth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 201999,China;2.Department of Oncology,Hainan Western Central Hospital,Hainan Danzhou 571831,China.
Keywords:
head and neck squamous cell carcinoma; NLR; PLR; immune checkpoint inhibitor
PACS:
R730.261
DOI:
10.3969/j.issn.1672-4992.2024.19.010
Abstract:
Objective:To explore the predictive value of baseline NLR and PLR for early efficacy in locally advanced head and neck squamous cell carcinoma（LA-HNSCC） patients receiving immunotherapy.Methods：This was a retrospective study of 52 patients with LA-HNSCC receiving PD-1 inhibitor combined with chemotherapy between January 2021 and December 2022.The combined impact of NLR,PLR and other clinical features was analyzed.The best cutoff values for NLR and PLR were derived using ROC curves.According to the best cutoff values of NLR and PLR,patients were divided into groups of high level NLR and PLR and groups of low level NLR and PLR.The impact of the two groups on early efficacy of neoadjuvant immunotherapy was analyzed.Results：In univariate analysis,disease status(P=0.002),PD-L1 expression(P=0.023),NLR(P=0.011) and PLR(P=0.024) were significantly associated with early efficacy of immunotherapy.Only disease status(P=0.018),NLR(P=0.009),and PLR(P=0.036) maintained a significant association with early efficacy of immunotherapy in multivariate analysis.Patients with baseline NLR＜6.85 had significantly better efficacy than patients with NLR≥6.85（P=0.004）,as did patients with baseline PLR＜173.7 and PLR≥173.7（P=0.036）.Conclusion：Low baseline NLR or PLR were associated with better immunotherapy efficacy in LA- HNSCC patients receiving immunotherapy.

References:

[1]ABRIL-RODRIGUEZ G,RIBAS A.Snapshot:Immune checkpoint inhibitors［J］.Cancer Cell,2017,31(6):848.
[2] FERRIS RL,BLUMENSCHEIN G JR,FAYETTE J,et al.Nivolumab for recurrent squamous-cell carcinoma of the head and neck［J］.N Engl J Med,2016,375(19):1856-1867.
[3] BURTNESS B,HARRINGTON KJ,GREIL R,et al.Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck(KEYNOTE-048):a randomised,open-label,phase 3 study［J］.Lancet,2019,394(10212):1915-1928.
[4] TOPALIAN SL,TAUBE JM,PARDOLL DM.Neoadjuvant checkpoint blockade for cancer immunotherapy［J］.Science,2020,367(6477):525.
[5] VERSLUIS JM,LONG GV,BLANK CU.Learning from clinical trials of neoadjuvant checkpoint blockade［J］.Nat Med,2020,26(4):475-484.
[6] FERRAROTTO R,BELL D,RUBIN ML,et al.Impact of neoadjuvant durvalumab with or without tremelimumab on CD8(+) tumor lymphocyte density,safety,and efficacy in patients with oropharynx cancer:CIAO trial results［J］.Clin Cancer Res,2020,26(13):3211-3219.
[7] FERRIS RL,SPANOS WC,LEIDNER R,et al.Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial［J］.J Immunother Cancer,2021,9(6):002568
[8] CHAE YK,PAN A,DAVIS AA,et al.Biomarkers for PD-1/PD-L1 blockade therapy in non-small-cell lung cancer:Is PD-L1 expression a good marker for patient selection［J］.Clin Lung Cancer,2016,17(5):350-361.
[9] GRIVENNIKOV SI,GRETEN FR,KARIN M.Immunity,inflammation,and cancer［J］.Cell,2010,140(6):883-899.
[10] DIAKOS CI,CHARLES KA,MCMILLAN DC,et al.Cancer-related inflammation and treatment effectiveness［J］.Lancet Oncol,2014,15(11):e493-503.
[11] KARAN C,YAREN A,DEMIREL BC,et al.Pretreatment PLR is preferable to NLR and LMR as a predictor in locally advanced and metastatic bladder cancer［J］.Cancer Diagn Progn,2023,3(6):706-715.
[12] MOSCA M,NIGRO MC,PAGANI R,et al.Neutrophil-to-lymphocyte ratio(NLR) in NSCLC,gastrointestinal,and other solid tumors:Immunotherapy and beyond［J］.Biomolecules,2023,13(12)：1803.
[13] YANG M,ZHANG J,WEI D,et al.Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab(PD-1 inhibitor) adjuvant therapy［J］.BMC Cancer,2024,24(1):196.
[14] ZHONG LP,ZHANG CP,REN GX,et al.Randomized phase III trial of induction chemotherapy with docetaxel,cisplatin,and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma［J］.J Clin Oncol,2013,31(6):744-751.
[15] WISE-DRAPER TM,GULATI S,PALACKDHARRY S,et al.Phase II clinical trial of neoadjuvant and adjuvant pembrolizumab in resectable local-regionally advanced head and neck squamous cell carcinoma［J］.Clin Cancer Res,2022,28(7):1345-1352.
[16] ZHANG Z,WU B,PENG G,et al.Neoadjuvant chemoimmunotherapy for the treatment of locally advanced head and neck squamous cell carcinoma:A single-arm phase 2 clinical trial［J］.Clin Cancer Res,2022,28(15):3268-3276.
[17] SAADA-BOUZID E,DEFAUCHEUX C,KARABAJAKIAN A,et al.Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma［J］.Ann Oncol,2017,28(7):1605-1611.
[18] NAKAYA A,KURATA T,YOSHIOKA H,et al.Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab［J］.Int J Clin Oncol,2018,23(4):634-640.
[19] PAN YC,JIA ZF,CAO DH,et al.Preoperative lymphocyte-to-monocyte ratio(LMR) could independently predict overall survival of resectable gastric cancer patients［J］.Medicine(Baltimore),2018,97(52):e13896.
[20] ZER A,SUNG MR,WALIA P,et al.Correlation of neutrophil to lymphocyte ratio and absolute neutrophil count with outcomes with PD-1 axis inhibitors in patients with advanced non-small-cell lung cancer［J］.Clin Lung Cancer,2018,19(5):426-434.
[21] 王澄宸，陈晓品.免疫治疗疗效标志物最新进展［J］.现代肿瘤医学，2020,28(02):346-350.WANG Chengchen,CHEN Xiaopin.The research progress of anti-PD-(L)1 and anti-CTLA-4 immunotherapy markers［J］.Modern Oncology,2020,28(02):346－350.
[22] 赵之标，毕明宏，李国祥.非小细胞肺癌免疫治疗前后NLR和PLR变化及对免疫治疗疗效的预测价值［J］.现代肿瘤医学，2022,30(4):613-618.ZHAO ZB,BI MH,LI GX.Changes of NLR and PLR before and after immunotherapy for non-small cell lung cancer and predictive value for the prognosis of immunotherapy［J］.Modern Oncology，2022,30(4):613-618.
[23] UEDA T,CHIKUIE N,TAKUMIDA M,et al.Baseline neutrophil-to-lymphocyte ratio(NLR) is associated with clinical outcome in recurrent or metastatic head and neck cancer patients treated with nivolumab［J］.Acta Otolaryngol,2020,140(2):181-187.
[24] MATSUO M,YASUMATSU R,MASUDA M,et al.Inflammation-based prognostic score as a prognostic biomarker in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with nivolumab therapy［J］.In Vivo,2022,36(2):907-917.
[25] TREFFERS LW,HIEMSTRA IH,KUIJPERS TW,et al.Neutrophils in cancer［J］.Immunol Rev,2016,273(1):312-328.
[26] TEMPLETON AJ,MCNAMARA MG,SERUGA B,et al.Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors:a systematic review and meta-analysis［J］.J Natl Cancer Inst,2014,106(6):dju124.
[27] LIANG W,FERRARA N.The complex role of neutrophils in tumor angiogenesis and metastasis［J］.Cancer Immunol Res,2016,4(2):83-91.
[28] HU W,LEE SML,BAZHIN AV,et al.Neutrophil extracellular traps facilitate cancer metastasis:cellular mechanisms and therapeutic strategies［J］.J Cancer Res Clin Oncol,2023,149(5):2191-2210.
[29] LIU D,YANG X,WANG X.Neutrophil extracellular traps promote gastric cancer cell metastasis via the NAT10-mediated N4-acetylcytidine modification of SMYD2［J］.Cell Signal,2024,116:111014.
[30] MASUCCI MT,MINOPOLI M,DEL VECCHIO S,et al.The emerging role of neutrophil extracellular traps(NETs) in tumor progression and metastasis［J］.Front Immunol,2020,11:1749.
[31] XIA J,ZHANG Z,HUANG Y,et al.Regulation of neutrophil extracellular traps in cancer［J］.Int J Cancer,2024,154(5):773-785.
[32] SABRKHANY S,GRIFFIOEN AW,OUDE EGBRINK MG.The role of blood platelets in tumor angiogenesis［J］.Biochim Biophys Acta,2011,1815(2):189-196.
[33] PARDOLL DM.The blockade of immune checkpoints in cancer immunotherapy［J］.Nat Rev Cancer,2012,12(4):252-264.
[34] ZHAO J,HUANG W,WU Y,et al.Prognostic role of pretreatment blood lymphocyte count in patients with solid tumors:a systematic review and meta-analysis［J］.Cancer Cell Int,2020,20:15.
[35] HO WJ,YARCHOAN M,HOPKINS A,et al.Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas［J］.J Immunother Cancer,2018,6(1):84.

Memo

Memo:
海南省自然科学基金项目（编号:824MS156）
Last Update: 2024-08-30